ATE255891T1 - Stabiles gabapentin, das mehr als 20 ppm chlor enthält - Google Patents

Stabiles gabapentin, das mehr als 20 ppm chlor enthält

Info

Publication number
ATE255891T1
ATE255891T1 AT01946364T AT01946364T ATE255891T1 AT E255891 T1 ATE255891 T1 AT E255891T1 AT 01946364 T AT01946364 T AT 01946364T AT 01946364 T AT01946364 T AT 01946364T AT E255891 T1 ATE255891 T1 AT E255891T1
Authority
AT
Austria
Prior art keywords
ppm chlorine
stable gabapentin
stable
gabapentin containing
ppm
Prior art date
Application number
AT01946364T
Other languages
English (en)
Inventor
Claude Singer
Gideon Pilarski
Michael Pesachovich
Edi Schwartz
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22788993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE255891(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE255891T1 publication Critical patent/ATE255891T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Detergent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
AT01946364T 2000-06-16 2001-06-15 Stabiles gabapentin, das mehr als 20 ppm chlor enthält ATE255891T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21196700P 2000-06-16 2000-06-16
PCT/US2001/019100 WO2001097612A1 (en) 2000-06-16 2001-06-15 Stable gabapentin containing more than 2o ppm of chlorine ion

Publications (1)

Publication Number Publication Date
ATE255891T1 true ATE255891T1 (de) 2003-12-15

Family

ID=22788993

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01946364T ATE255891T1 (de) 2000-06-16 2001-06-15 Stabiles gabapentin, das mehr als 20 ppm chlor enthält

Country Status (12)

Country Link
US (1) US6531509B2 (de)
EP (1) EP1289364B1 (de)
AT (1) ATE255891T1 (de)
AU (1) AU2001268426A1 (de)
CA (1) CA2410867C (de)
DE (2) DE1289364T1 (de)
DK (1) DK1289364T3 (de)
ES (1) ES2193008T3 (de)
IL (1) IL153398A0 (de)
PT (1) PT1289364E (de)
TR (1) TR200302296T4 (de)
WO (1) WO2001097612A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100667721B1 (ko) * 2000-06-16 2007-01-15 테바 파마슈티컬 인더스트리즈 리미티드 제어 범위 내의 ｐｈ를 갖는 안정한 가바펜틴
US7056951B2 (en) 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20030119908A1 (en) * 2001-12-21 2003-06-26 Zambon Group S.P.A. Stable gabapentin compositions
JP2006511624A (ja) * 2002-12-20 2006-04-06 ダイノジェン ファーマシューティカルズ， インコーポレイテッド α２δサブユニット・カルシウム・チャンネル調節因子を使用する無痛性膀胱障害を処置するための方法
ES2275229T3 (es) * 2003-03-21 2007-06-01 Dynogen Pharmaceuticals, Inc. Metodos para el tratamiento de desordenes del tracto urinario iferior utilizando antimuscarinos y moduladores de la subunidad alfa-2-delta del canal de calcio.
WO2005046566A2 (en) * 2003-08-04 2005-05-26 Sun Pharmaceutical Industries Limited Stable gabapentin containing composition
US20050163850A1 (en) * 2003-10-31 2005-07-28 Wong Patrick S. Administration of levodopa and carbidopa
US20050187295A1 (en) * 2004-02-19 2005-08-25 Surendra Kalyan Processes for the preparation of gabapentin
US20070092565A1 (en) * 2005-10-25 2007-04-26 Pharmascience Inc. Gastric retention drug delivery system
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
CN101462975B (zh) * 2008-08-19 2012-07-25 宁波九胜创新医药科技有限公司 一种高纯度加巴喷丁的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2611690A1 (de) 1976-03-19 1977-09-22 Goedecke Ag Cyclische sulfonyloxyimide
US4960931A (en) 1988-05-02 1990-10-02 Warner-Lambert Company Gabapentin mohohydrate and a process for producing the same
US4894476A (en) 1988-05-02 1990-01-16 Warner-Lambert Company Gabapentin monohydrate and a process for producing the same
US5319135A (en) 1989-08-25 1994-06-07 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
DE3928182A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von gabapentin
FI107914B (fi) 1989-08-25 2001-10-31 Warner Lambert Co Parannettu menetelmä syklisten aminohappoyhdisteiden valmistamiseksi ja menetelmässä käytettävä välituote
DE3928184A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von cyclischen aminosaeurederivaten sowie zwischenprodukte
DE3928183A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US5132451A (en) 1989-08-25 1992-07-21 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
US5084479A (en) 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US5025035A (en) 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
IL119890A (en) * 1996-12-24 2002-03-10 Teva Pharma Gabapentin form iii and preparation of gabapentin form ii
BR9910508B1 (pt) * 1998-05-15 2012-01-24 preparações farmacêuticas estabilizadas de derivados de ácido gama-aminobutìrico.
AU769038B2 (en) * 1998-05-15 2004-01-15 Warner-Lambert Company Llc Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same
FR2781793B1 (fr) 1998-08-03 2001-07-20 Prographarm Lab Procede de fabrication de granules de gabapentine enrobes
US6294198B1 (en) 1999-08-24 2001-09-25 Purepac Pharmaceutical Co. Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same

Also Published As

Publication number Publication date
CA2410867A1 (en) 2001-12-27
US6531509B2 (en) 2003-03-11
ES2193008T1 (es) 2003-11-01
DE1289364T1 (de) 2003-09-18
IL153398A0 (en) 2003-07-06
AU2001268426A1 (en) 2002-01-02
TR200302296T4 (tr) 2004-02-23
US20020061931A1 (en) 2002-05-23
EP1289364A4 (de) 2003-08-06
EP1289364B1 (de) 2003-12-10
ES2193008T3 (es) 2004-07-01
WO2001097612A1 (en) 2001-12-27
DE60101476T2 (de) 2004-05-27
CA2410867C (en) 2003-12-09
PT1289364E (pt) 2004-04-30
DE60101476D1 (de) 2004-01-22
DK1289364T3 (da) 2004-04-13
EP1289364A1 (de) 2003-03-12

Similar Documents

Publication Publication Date Title
DE60101476D1 (de) Stabiles gabapentin, das mehr als 20 ppm chlor enthält
ATE357902T1 (de) Zusammensetzungen enthaltend ein solubilisiertes säuereangereichtes antischweissmiteel
IT1254571B (it) Composizione farmaceutica per applicazione topica, quale smalto per unghie.
DE60008369D1 (en) N-cyanomethylamide als protease-inhibitoren
ES2130575T3 (es) Composiciones inmunogenicas mejoradas contra la gastrina 17 humana.
BR0209020A (pt) Composição farmacêutica de polialilamina
GB9920281D0 (en) Novel compositions of biologically active agents and their use
ATE380174T1 (de) Arginin-mimetika als faktor xa-inhibitoren
MXPA05012437A (es) Composiciones, dispositivos y metodos para estabilizar e intensificar la eficacia del dioxido de halogeno.
ATE393205T1 (de) Brausezusammensetzungen
ECSP056227A (es) Composición blanqueadora de cloro reductora de olor de blanqueado
DK0937043T3 (da) Substituerede tetrahydropyridin-derivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse derivater
BR9611101A (pt) Composição cosmética transparente em bastão
BR0311590A (pt) Agonistas de brs-3 não-peptìdicos
IL159493A0 (en) Pharmaceutical formulation containing an ltb4 antagonist
ATE400580T1 (de) Chemische synthese von solamargin
AU2002210537A1 (en) (4-acylaminopiperidin-1-yl) acetamides as neurokinin antagonists
FR2862957B1 (fr) Composition comprenant du chlorate de sodium, nac103, ainsi que des compositions la contenant
Willis Mercury Rising
BR0115764A (pt) Composições, contendo copolìmeros à base de ácido acriloildimetiltaurìnico e aditivos sinergìsticos
ATE168683T1 (de) Substituierte iminoacetonitrile mit myokardprotektiver wirkung
AU2001289646A1 (en) Process for the debromination of an aqueous salt solution using ozone
BR0101880A (pt) Uma nova composição farmacêutica
RU2002120345A (ru) Средство "пипользин" антигистаминного действия
MY130184A (en) Dermal anesthetic agents

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1289364

Country of ref document: EP

RZN Patent revoked